Judge rules against HHS cuts to teen pregnancy prevention programs

Reproductive health was dealt multiple wins in the courts last week. (NataliaDeriabina)

Reproductive rights advocates scored a number of wins in the federal courts last week.

On Thursday, a federal judge in D.C. ruled against cuts by the U.S. Department of Health and Human Services to the Teen Pregnancy Prevention Program. The case involved four of more than 80 organizations that were told their five-year grants to the program that were originally set to end in 2020 would instead be cut in 2018, The Hill reported

The judge in the case ordered HHS to process of the applications of the four grantees involved. HHS did not respond with comment to the publication.

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

RELATED: HHS Awards Evidence-Based Teen Pregnancy Prevention Grants

In a separate case, the 7th U.S. Circuit Court of Appeals in Chicago ruled Indiana's ban on selective abortions is "unconstitutional."

The ban, which was meant to block abortions based on the gender, race or disability of a fetus, was signed into law in 2016 by the-Gov. Mike Pence, Reuters reported.

“The Supreme Court has been clear: the State may inform a woman’s decision before viability, but it cannot prohibit it,” Judge William Bauer wrote in the decision.

RELATED: Trump administration gives health workers who oppose abortion new protections

Suggested Articles

Industry group CHIME is urging federal healthcare policy officials to go slow with dual interoperability and information blocking rules.

JPMorgan Chase & Co. said on Friday that it plans to acquire InstaMed, a U.S. healthcare payments technology firm.

Friday, CMS announced a delay in its final national coverage determination for chimeric antigen receptor T-cell therapy.